Dynavax Technologies Corporation

Emeryville,  CA 
United States
  • Booth: 904

Welcome to our booth! Natalie Taylor (ntaylor@dynavax.com)

Dynavax Technologies is dedicated to developing innovative vaccines that modulate the immune system to prevent infectious diseases. We are the maker of the first and only 2-dose, over 1 month, hepatitis B vaccine for adults: Heplisav-B. The traditional 3-dose vaccines are associated with lower effectiveness and poor completion rates. In fact, ~75% of adults aged 19+ do not receive all 3 doses and remain under or unprotected and at-risk for acquiring hepatitis B. Heplisav-B addresses many of the limitations of the 3-dose vaccines and improves health outcomes, efficiency and can reduce overall healthcare costs.

Hepatitis B vaccines have been available for over 30 years, yet HBV infections are on the rise. Estimated new cases of hepatitis B have risen ~11% over a 5-year period and as many as 2.2 million people are infected with hepatitis B in the United States.


  • Heplisav-B
    Dynavax is a biopharmaceutical company that developed an FDA approved Hepatitis-B vaccine that offers a two-dose vaccine over 1-month option to adult patients....

  • Dynavax is a commercial-stage biopharmaceutical company.  Our FDA-approved 
    Hepatitis B vaccine is the only two-dose hepatitis vaccine for adults that completes the series in 1 month.  It is the first approved hepatitis B vaccine in over 25 years and received a unanimous recommendation from the Advisory Committee on Immunization Practice.

Send Email

Type your information and click "Send Email" to send an email to this exhibitor. To return to the previous screen without saving, click "Reset".